SBH
IART icon

Segall Bryant & Hamill’s Integra LifeSciences IART Stock Holding History

Segall Bryant & Hamill’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-53,393
Closed -$1.89M – 425
2024
Q1 		$1.89M Sell
53,393
-117,396
-69% -$4.7M 0.04% 279
2023
Q4 		$7.44M Buy
170,789
+4,865
+3% +$191K 0.14% 228
2023
Q3 		$6.34M Sell
165,924
-9,541
-5% -$401K 0.07% 285
2023
Q2 		$7.22M Buy
175,465
+463
+0.3% +$22.3K 0.08% 288
2023
Q1 		$10M Sell
175,002
-77,203
-31% -$4.35M 0.11% 230
2022
Q4 		$14.1M Buy
252,205
+14,274
+6% +$727K 0.16% 176
2022
Q3 		$10.1M Buy
237,931
+31,566
+15% +$1.62M 0.12% 205
2022
Q2 		$11.1M Buy
206,365
+47,391
+30% +$2.85M 0.13% 182
2022
Q1 		$10.2M Buy
158,974
+199
+0.1% +$13.1K 0.1% 216
2021
Q4 		$10.6M Buy
158,775
+48,754
+44% +$3.3M 0.1% 207
2021
Q3 		$7.54M Sell
110,021
-65,161
-37% -$4.6M 0.07% 251
2021
Q2 		$12M Buy
175,182
+15,525
+10% +$1.1M 0.12% 195
2021
Q1 		$11M Sell
159,657
-23,286
-13% -$1.58M 0.11% 199
2020
Q4 		$11.9M Buy
182,943
+13,831
+8% +$744K 0.13% 173
2020
Q3 		$7.99M Buy
169,112
+54,106
+47% +$2.57M 0.11% 190
2020
Q2 		$5.4M Buy
115,006
+6,010
+6% +$295K 0.09% 208
2020
Q1 		$4.87M Sell
108,996
-7,531
-6% -$395K 0.1% 199
2019
Q4 		$6.79M Buy
116,527
+1,947
+2% +$116K 0.11% 195
2019
Q3 		$6.88M Sell
114,580
-26,062
-19% -$1.55M 0.11% 223
2019
Q2 		$7.86M Sell
140,642
-10,721
-7% -$552K 0.12% 209
2019
Q1 		$8.43M Buy
151,363
+1,626
+1% +$82.8K 0.13% 199
2018
Q4 		$6.75M Buy
149,737
+16,021
+12% +$879K 0.12% 221
2018
Q3 		$8.81M Buy
133,716
+10,079
+8% +$626K 0.13% 211
2018
Q2 		$7.96M Buy
123,637
+5,017
+4% +$311K 0.12% 221
2018
Q1 		$6.56M Sell
118,620
-7,372
-6% -$386K 0.15% 156
2017
Q4 		$6.03M Buy
125,992
+13,472
+12% +$659K 0.13% 174
2017
Q3 		$5.68M Buy
112,520
+19,486
+21% +$1M 0.13% 170
2017
Q2 		$5.07M Buy
+93,034
New +$4.44M 0.12% 186

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Segall Bryant & Hamill's IART Position: Q2 2024 in Review

Segall Bryant & Hamill sold out of Integra LifeSciences (IART) in Q2 2024, closing a stake of 53,393 shares — an estimated $1.89M sold.

Segall Bryant & Hamill first reported a position in IART in Q2 2017 and held it in 28 quarters. The position peaked at $14.1M in Q4 2022. 238 funds tracked by Wall St. Rank hold IART as of Q2 2024.

  • Segall Bryant & Hamill reported no remaining Integra LifeSciences position as of Q2 2024 after selling out during the quarter.
  • Segall Bryant & Hamill sold 53,393 Integra LifeSciences shares in Q2 2024, an estimated $1.89M.
  • Segall Bryant & Hamill first reported a position in Integra LifeSciences in Q2 2017 and held it in 28 quarters.
  • Segall Bryant & Hamill's Integra LifeSciences position peaked at $14.1M in Q4 2022.
  • 238 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2024.

Based on Segall Bryant & Hamill's 13F filing for Q2 2024, filed 14 Aug 2024.